DKM Wealth Management’s AbCellera Biologics ABCL Stock Holding History

DKM Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.5K	Hold	10,000	–	–	0.05%	65
2026 Q1	$34.9K	Hold	10,000	–	–	0.03%	67
2025 Q4	$34.2K	Hold	10,000	–	–	0.03%	69
2025 Q3	$50.3K	Hold	10,000	–	–	0.04%	62
2025 Q2	$34.3K	Hold	10,000	–	–	0.03%	56
2025 Q1	$22.3K	Hold	10,000	–	–	0.02%	50
2024 Q4	$29.3K	Buy	+10,000	New	+$27.8K	0.03%	52

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

DKM Wealth Management's ABCL Position: Q2 2026 in Review

DKM Wealth Management held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 10,000 shares worth $78.5K. The position accounts for 0.05% of the portfolio, ranked #65.

DKM Wealth Management first reported a position in ABCL in Q4 2024 and has held it in 7 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

DKM Wealth Management held 10,000 shares of AbCellera Biologics worth $78.5K as of Q2 2026.
DKM Wealth Management left its AbCellera Biologics share count unchanged in Q2 2026.
AbCellera Biologics made up 0.05% of DKM Wealth Management's portfolio in Q2 2026, its #65 holding.
DKM Wealth Management first reported a position in AbCellera Biologics in Q4 2024 and has held it in 7 quarters since.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on DKM Wealth Management's 13F filing for Q2 2026, filed 30 Jul 2026.